Namal P M Liyanage

List of Publications by Year
in descending order

27	711	623734	580821
papers	citations	14 h-index	25 g-index

32	32	32	1170
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology. Journal of Hematology and Oncology, 2022, 15, 5.	17.0	30
2	Tissue-localized immune responses in people with cystic fibrosis and respiratory nontuberculous mycobacteria infection. JCI Insight, 2022, 7, .	5.0	5
3	Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. IScience, 2021, 24, 102047.	4.1	16
4	Inhibition of elastase enhances the adjuvanticity of alum and promotes antiâ€“SARS-CoV-2 systemic and mucosal immunity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	15
5	Lung T-Cell Profile Alterations are Associated with Bronchiolitis Obliterans Syndrome in Cystic Fibrosis Lung Transplant Recipients. Lung, 2020, 198, 157-161.	3.3	7
6	Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections. Frontiers in Immunology, 2020, 11, 1979.	4.8	25
7	Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition. PLoS Pathogens, 2020, 16, e1008377.	4.7	14
8	Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques. Journal of Virology, 2020, 94, .	3.4	8
9	Attenuation of Helper T Cell Capacity for TH1 and TH17 Differentiation in Children With Nontuberculous Mycobacterial Infection. Journal of Infectious Diseases, 2019, 220, 1843-1847.	4.0	4
10	ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type. PLoS Pathogens, 2019, 15, e1008121.	4.7	19
11	HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition. Nature Medicine, 2018, 24, 847-856.	30.7	65
12	Stool antigen immunodetection for diagnosis of Giardia duodenalis infection in human subjects with HIV and cancer. Journal of Microbiological Methods, 2017, 141, 35-41.	1.6	13
13	Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. Journal of Immunology, 2016, 197, 2726-2737.	0.8	34
14	Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nature Medicine, 2016, 22, 762-770.	30.7	197
15	Glucocorticoid Treatment at Moderate Doses of SIV_{mac251}-Infected Rhesus Macaques Decreases the Frequency of Circulating CD14⁺CD16⁺⁺Monocytes But Does Not Alter the Tissue Virus Reservoir. AIDS Research and Human Retroviruses, 2015, 31, 115-126.	1.1	15
16	Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques. Clinical Immunology, 2014, 155, 91-107.	3.2	24
17	Antibody to the gp120 V1/V2 Loops and CD4+ and CD8+ T Cell Responses in Protection from SIVmac251 Vaginal Acquisition and Persistent Viremia. Journal of Immunology, 2014, 193, 6172-6183.	0.8	34
18	Modulation of RAS Pathways as a Biomarker of Protection against HIV and as a Means to Improve Vaccine Efficacy. AIDS Research and Human Retroviruses, 2014, 30, A99-A99.	1.1	2

#	Article	IF	Citations
19	Do CD16+NKG2A+NK Cells Recruited to the Gut Combined with Passively Administered SIV Specific Antibodies Prevent SIV_{mac251} Acquisition in Macaques?. AIDS Research and Human Retroviruses, 2014, 30, A15-A15.	1.1	1
20	Adjuvant Dependent Mucosal V2 Responses and RAS Activation in Vaccine Induced Protection from SIV_{mac251} Acquisition. AIDS Research and Human Retroviruses, 2014, 30, A64-A65.	1.1	3
21	Antiretroviral therapy partly reverses the systemic and mucosal distribution of NK cell subsets that is altered by SIVmac251 infection of macaques. Virology, 2014, 450-451, 359-368.	2.4	18
22	Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses. Clinical Immunology, 2014, 153, 308-322.	3.2	20
23	Contribution of Helicobacter hepaticus Cytolethal Distending Toxin Subunits to Human Epithelial Cell Cycle Arrest and Apoptotic Death in vitro. Helicobacter, 2013, 18, 433-443.	3.5	11
24	RV144-like trial in macaques using ALVAC-SIV & gp120 induces innate immunity and increases the frequency of NK22 & NKG2A+ cells in mucosal tissues. Retrovirology, 2012, 9, .	2.0	1
25	Helicobacter hepaticus Cytolethal Distending Toxin Causes Cell Death in Intestinal Epithelial Cells via Mitochondrial Apoptotic Pathway. Helicobacter, 2010, 15, 98-107.	3.5	39
26	Regulation of the bioavailability of thioredoxin in the lens by a specific thioredoxin-binding protein (TBP-2). Experimental Eye Research, 2007, 85, 270-279.	2.6	20
27	Seroprevalence of varicella zoster virus infections in Colombo District, Sri Lanka. Indian Journal of Medical Sciences, 2007, 61, 128.	0.1	38